Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...

Diabetes technology innovators gathered last week for the Advanced Technologies and Treatments for Diabetes Conference (ATTD 2026).

Dexcom reported second-quarter results on Friday, July 26. Management lowered its forward revenue outlook because of unexpected challenges with its new glucose monitoring device. Dexcom's main ...

This is now a Class I recall, meaning that the use of these continuous glucose monitoring systems could cause serious health consequences or death. Anna Gragert (she/her/hers) was previously the ...